Hôpital Rangueil - CHU de Toulouse | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases	interstitial lung disease, lung disorder, respiratory system disorder	Active, not recruiting	Phase 3	2026-10-02		NCT06806592
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis	Metabolic Dysfunction Associated Steatohepatitis	Recruiting	Phase 3	2026-10-01		NCT06632457
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis	Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder	Recruiting	Phase 3	2026-10-01		NCT06632444
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies	acquired idiopathic inflammatory myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease	Not yet recruiting	Phase 3	2026-09-30		NCT07789015
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder	Recruiting	Phase 3	2026-09-30		NCT07064473
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy	Extrapulmonary Neuroendocrine Cancer (epNEC)	Recruiting	Phase 3	2026-09-29		NCT07544654